Rapid response to dupilumab treatment in children with moderate‐to‐severe atopic dermatitis: A case series

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by itch and clinical heterogeneity regarding the age of onset, morphology, distribution, and severity of lesions. Severe AD has a significant impact on the quality of life of affected children and their caregiver...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric allergy and immunology 2022-01, Vol.33 (S27), p.31-33
Main Authors: Votto, Martina, Delle Cave, Francesco, De Filippo, Maria, Marseglia, Alessia, Marseglia, Gian Luigi, Brazzelli, Valeria, Licari, Amelia, Del Giudice, Michele Miraglia
Format: Article
Language:English
Subjects:
Age composition
allergy
Antibodies, Monoclonal, Humanized
Atopic dermatitis
Child
Children
Corticosteroids
Dermatitis
Dermatitis, Atopic - drug therapy
dupilumab
Eczema
Humans
Inflammatory diseases
Monoclonal antibodies
Pediatrics
Phototherapy
Quality of Life
Severity of Illness Index
Skin diseases
Special Issue: 2021 Update From The Italian Society Of Pediatric Allergy And Immunology
Supplement
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease characterized by itch and clinical heterogeneity regarding the age of onset, morphology, distribution, and severity of lesions. Severe AD has a significant impact on the quality of life of affected children and their caregivers. Children with moderate‐severe AD inadequately controlled with topical therapy have limited treatment options, such as systemic corticosteroids or phototherapy, often prescribed as off‐label treatments, often with unfavorable benefit‐to‐risk ratio adverse events. Dupilumab is a fully human monoclonal antibody with proven effectiveness and a relatively safe adverse effect profile in patients with type 2 inflammatory diseases, including AD. We report three pediatric cases of severe AD successfully treated with dupilumab.
ISSN:0905-6157
1399-3038
DOI:10.1111/pai.13623